We combine biotechnology and pharmaceutical know-how to make an impact in the wellbeing of millions of people around the world.
We focus on the three initial stages of drug development: In vitro, Pre-Clinical Studies, Safety and therapeutic effectivity clinical studies.
Our initial therapeutic target is on refractory chronic wound healing reassembly.
Studying Chronic Wounds.
For the past 15 years we have studied different types of wounds that take months to years to heal, which sometimes never occurs. Some of these wound types include:
- diabetic foot
- pressure ulcers
- venous ulcers
- arterial ulcers
- postsurgical wounds infected with biofilm forming bacteria
Therapeutic rationale.
The majority of chronic wounds are infected with biofilm forming bacteria. Biofilm is a community of bacteria that secrete a biological matrix as a physical barrier to protect themselves from the outside environment. This makes them resistant to antiseptics and antibiotics.
Broad spectrum biofilm elimination is a key part of a successful protocol of care, however, this is challenging and all approaches to date have proved unsuccessful.
Inventing a solution.
We tested different prototypes and finally developed and perfected a gel that covers the three main therapeutical requirements, working as:
- Anti-pathogenic (Bacteriostatic, bactericidal and biofilm disruptor of 95 % infecting bacteria)
- Anesthetic
- Pro-healing (inhibition of MMPs and free radicals, wound oxygenation, collagenization
Besides, our gel allows the patient to apply the treatment without recurring to a healthcare facility and successfully healing chronic wounds for the first time in history.
